VBI Vaccines to Present at September 2017 Investor Conferences
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Sept. 12, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) (VBI)
today announced that Jeff Baxter, President and CEO, will provide a corporate overview and update at two investor conferences in
September.
- VBI will present at the Cantor Fitzgerald Global Healthcare Conference at 10:55 a.m. EDT on Tuesday, Sept. 26, 2017
- VBI will present at the Ladenburg Thalmann 2017 Healthcare Conference at 2:30 p.m. EDT on Tuesday, Sept. 26, 2017
Live webcasts will be available on the Investors page of VBI's website at: www.vbivaccines.com/investors/events-presentations/. A replay of
each presentation will be available at the same location for 90 days following the events.
About VBI Vaccines Inc.
VBI Vaccines Inc. ("VBI") is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address
unmet needs in infectious disease and immuno-oncology. VBI's first marketed product is Sci-B-Vac™, a hepatitis B (HBV) vaccine
that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other
countries. VBI's eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that
closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead
programs in cytomegalovirus (CMV) and glioblastoma multiforme (GBM). VBI is also advancing its LPV™ Thermostability Platform, a
proprietary formulation and process that enables vaccines and biologics to preserve stability, potency, and safety. VBI is
headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot,
Israel.
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of
1995 and are forward-looking information within the meaning of Canadian securities laws (collectively "forward-looking
statements"). The company cautions that such statements involve risks and uncertainties that may materially affect the company's
results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and
information currently available to management. Actual results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential
products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the
development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential
products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on
commercially reasonable terms; the company's ability to manufacture product candidates on a commercial scale or in collaborations
with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the
ability to secure and enforce legal rights related to the company's products, including patent protection. A discussion of these
and other factors, including risks and uncertainties with respect to the company, is set forth in the Company's filings with the
Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with
the Securities and Exchange Commission on March 20, 2017, and filed with the Canadian security authorities at sedar.com on March
24, 2017, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The company disclaims any intention
or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.